Correlation between Plasma Osteopontin and Alkaline Phosphatase in Type 2 Diabetes Mellitus Patients

Josua TH Sinambela, M.I Diah Pramudianti, Dian Ariningrum


Diabetes Mellitus (DM) is a chronic disease caused by pancreas the inability to produce insulin or ineffectively insulin use.
Fracture risk in type 2 DM patients increases even though the bone density is normal. This study aimed to examine the
correlation of osteopontin (OPN) and alkaline phosphatase (ALP) in type 2 DM patients. An observational analytical study
was conducted in 73 type 2 DM patients in Dr. Moewardi Hospital, Surakarta from October to November 2018. The subjects
were examined for blood pressure, fasting blood glucose, two hours postprandial blood glucose, HbA1c, OPN, and ALP
levels. P-value <0.05 was statistically significant with a 95% confidence interval. Poorly controlled type 2 DM had higher OPN
levels than well-controlled (20.5±2.8 vs. 14.8±3.1 ng/mL, p <0.001). The ALP concentration was also higher in poorly
controlled type 2 DM patients (79.9±31.7 vs. 61.1±25 U/L, p=0.003). The levels of OPN and ALP were significantly correlated
in type 2 diabetes (r=0.273; p=0.020) and in well-controlled patients (r=0.353; p=0.047) but no correlation was found in
poorly controlled type 2 DM patients (r= -0.073; p= 0.652). In this study, a significant correlation was found between OPN
and ALP in patients with type 2 DM and well-controlled. Further study involving healthy controls and bone ALP
measurement is needed.


Type 2 diabetes mellitus, osteopontin, alkaline phosphatase

Full Text:



World Health Organization (WHO). Global report on diabetes, WHO press, Geneva, 2016; 6–11.

Perkumpulan Endokrinologi Indonesia (PERKENI). Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. PB PERKENI 2015; 1-11.

Riset Kesehatan Dasar (RISKESDAS). Balai penelitian dan pengembangan kesehatan kementerian kesehatan RI. Jakarta. 2013; 87-90.

Botolin S, Mccabe L. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology, 2007; 148: 198-205.

Vestergaard P. Diabetes and bone, J Diabetes Metab.2011; 1-7.

Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study, J Clin Endocrinol Metab. 1998; 83: 4257-4262.

Zhou Z, Immel D, Xi C, Bierhaus A, Feng X, Mei L, Nawroth P, et al. Regulation of osteoclast function and bone mass by RAGE, J Exp Med. 2006; 203: 1067-1080.

Kahles F, Findelsen HM, Bruemmer D. Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes, J Molmet. 2014; 3: 384-393.

Icer MA, Karadag MG. The multiple functions and mechanisms of osteopontin, J Clinbiochem. 2018; 1-18

Nomiyama T, Perez TD, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice, The Journal of Clinical Investigation. 2007; 10: 2877-2888.

Sodhi CP, Phadke SA, Battle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin, American Journal of Physiology-Renal Physiology. 2001; 280(4): F667-F674.

Sun J, Xu Y, Deng H, Sun S, Dai Z, Sun Y. Involvement of osteopontin upregulation on mesangial cell growth and collagen synthesis induced by intermittent high glucose, Journal of Cellular Biochemistry. 2010; 109(6): 1210-1221.

Deepika G, Veeraiah N, Naved S, Ramana MV. Serum alkaline phosphatase and high sensitivity C-reactive protein in type II diabetes mellitus: a risk of cardiovascular disease in south indian population, Int J Res Med Sci. 2016; 4(4): 1107-1114.

Sultan E, Taha I, Saber LM. Altered bone metabolic markers in type 2 diabetes mellitus: impact of glycemic control, J T U Med Sc. 2008; 3(2): 104-116.

Fodor D, Bondor C, Albu A, Simon S, Craciun A, Muntean L. The value of osteopontin in the assesment of bone mineral density status in postmenopausal women, J Investig Med. 2013; 61: 15-21.

Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausel woman. Osteoporos. 2010; 21(8): 1401-9.

Gordin D, Forsblom C, Panduru NM, Thomas MC, Bjerre M, Paavonen AS, Tolonen N, Et al. Osteopontin in a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all cause mortality in patients with type 1 diabetes, Diabetes Care, 2014; 1-8.

Barchetta L, Alessandri C, Bertoccini L, Cimini FA, Taverniti L, Di Franco M, Fraioli A, et al. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur J Endocrinol. 2016; 174: 187-192.

Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations, Endocrinology, 2008; 149: 1350-1357.

Amanullah S, Jarari A, Govindan M. Association of hsCRP with diabetic and non-diabetic individuals. Jordan J Biol Sci. 2010; 3(1): 7-12.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.